Close

What are ADC's

Our services

ADC Review
is made possible by:




Package Inserts -Antibody-drug Conjugates

Year Approved**
Drug (INN)* Trade Name Developer FDA Europe
Gemtuzumab Ozogamicin Maylotarg® Wyeth/Pfizer 2000
(Witdrawn)
2000
(Witdrawn)
Gemtuzumab Ozogamicin Maylotarg® Wyeth/Pfizer 2017
(Reintroduced)
Brentuximab Vedodin Adcetris® Seattle Genetics / Takeda 2011 2012
Ado-trastuzumab emtansine Kadcyla® Genentech/Roche 2013 2013
Inotuzumab Ozogamicin Besponsa® Wyeth/Pfizer 2017 2017

* Link to drug description
** Link to package insert


Last Editorial Review: August 28, 2017

Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar